Funding for this research was provided by:
Università degli Studi di Padova (DOR funds)
National Heart, Lung, and Blood Institute (HL139054, HL132523, HL130045, HL091889, HL098112, HL149744, HL056177)
National Institute of Environmental Health Sciences (ES006614)
National Institute of Allergy and Infectious Diseases (AI126614)
NIH Office of the Director (OD023282)
University of Arizona (RII COVID-19 seed grant (#002196), TRIF grant)
National Institute of Diabetes and Digestive and Kidney Diseases (DK103126)
National Institute of General Medical Sciences (GM136853)
Flight Attendant Medical Research Institute (YFAC141004)
Received: 19 April 2021
Accepted: 11 August 2021
First Online: 23 August 2021
: The study conformed to the Declaration of Helsinki, and the work was approved by the institutional local ethic committees (University of Arizona IRB #1811124026 and University of Ferrara IRB #080399). Informed written consent was obtained from each subject. All the murine studies were approved by the Brigham and Women’s Hospital (BWH) IACUC Committee, and performed in compliance with the BWH IACUC and ARRIVE guidelines.
: All the authors consent for publication of this manuscript.
: M. Contoli has received personal fees from Chiesi, AstraZeneca, Boehringer-Ingelheim, Alk-Abello, GSK, Novartis, Zambon, and scientific grants from Chiesi and University of Ferrara, Italy. A. Papi: Board membership, consultancy, payment for lectures, grants for research, travel expenses reimbursement from GSK, AZ, Boehringer Ingelheim, Chiesi Farmaceutici, TEVA, Mundipharma, Zambon, Novartis, Menarini, Sanofi,Roche, Edmondpharma, Fondazione Maugeri, Fondazione Chiesi. None of the other authors have competing conflicts of interest to declare.